IsoPlexis publishes a preliminary full year 2021

0


BRAFORD, Connecticut, January 9, 2022 (GLOBE NEWSWIRE) – IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for full year 2021. Total revenue for 2021 is expected to be between 17.0 and $ 17.2 million, an increase of about 64% to 66%. against $ 10.4 million for the whole of 2020.

Since the commercial launch in 2018, Isoplexis has placed 209 instruments in total, including 98 new instruments sold in 2021. At the end of the year, IsoPlexis achieved a milestone with 67% of the complete cancer centers in the United States and in addition, 100% of the top 15 pharma companies now use IsoPlexis for the functional analysis of cells.

IsoPlexis also today unveiled the Superhuman Cell Library, an industry-first mapping of proteomic cells, unique to the IsoPlexis platform, which determines how the human body responds to a complex disease. By identifying a comprehensive range of rare but important supercells, the library categorizes how these cells have been used to predict patient response to therapy in a wide range of clinically relevant journals. The library also lays the groundwork for customers to continue to add characterization to these unique predictor cells to advance human health overall.

“Our revenue growth in 2021 reinforces the value of our platform and how, with the release of The Superhuman Cell Library, IsoPlexis is taking the lead in advancing the future of medicine and healthcare,” said Sean Mackay, CEO of IsoPlexis. “The IsoPlexis platform enables researchers to discover superhero cells and superhuman biology for the first time, opening up unprecedented perspectives on the development of therapies for the world’s most difficult diseases. “

These preliminary results are based on the initial analysis of management’s operations for the quarter ended December 31, 2021. The company expects to release full financial results for the fourth quarter and full year 2021 at the end of February 2022.

The Superhuman Cell Library provides a comprehensive definition of cells driven by proteomics which is leading to major advances in the way diseases are diagnosed and treated. It is a valuable resource for oncology, immunology, infectious diseases, neurology, inflammatory diseases, and cell and gene therapy. It is now available as an industry-wide resource, referenced in the literature and constantly updated at http://isoplexis.com/FCL.

“Following the publications of the Atlas of Human Cells and the Atlas of the Human Genome, definitions of the functional proteome of each cell are essential to advance our understanding of human cell behavior. By mapping our bodies’ most functionally active immune cells, or cellular ‘superheroes’, IsoPlexis is making a key contribution to improving our understanding of the power of every cell in the human body, ”said James R. Heath Ph.D. Dr. Heath is president and professor at the Institute for Systems Biology in Seattle and professor of bioengineering at the University of Washington. He is also co-founder and member of the scientific board of IsoPlexis.

About IsoPlexis
IsoPlexis is the Superhuman Cell company.

IsoPlexis systems uniquely identify a full range of multifunctional single cells, that is, superhero cells in the human body. These cells allow researchers to understand and predict disease progression, resistance to treatments, and therapeutic efficacy in advancing overall human health.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and many others. The IsoPlexis platform is used worldwide by researchers, including those from the world’s 15 largest pharmaceutical companies and two-thirds of the major cancer centers in the United States.

Caution regarding forward-looking statements
This press release contains “forward-looking statements”. These statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based on our current beliefs, expectations and assumptions about the future of our business, our future plans and strategies, and other future conditions. These forward-looking statements may include, without limitation, statements about future opportunities for us and our products and services, our future operations, our financial or operational results, including our financial directions, expected levels of activity, future profits, planned activities, expected growth, market opportunities, strategies, competitions and other expectations and goals for future periods. In some cases, you can identify forward-looking statements because they contain words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “predict” “,” Plan “,” “target”, “potential”, “seek”, “want”, “want”, “could”, “should”, “continue”, “consider”, “plan” and others words and terms with similar meanings. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that forward-looking statements are not guarantees of future performance or results and that actual performance and results may differ materially from those made or suggested by the forward-looking statements contained in this press release. In addition, although our results of operations, our financial condition and our cash flows, as well as the development of the markets in which we operate, are consistent with the forward-looking statements contained in this press release, these results or developments may not not be indicative of results or developments in subsequent periods. New factors emerge from time to time that may prevent our business from growing as we expect, and it is impossible for us to predict all of them.

Factors that could cause actual results to differ from those reflected in forward-looking statements include, among others, the following: estimates of our target market, market growth, future revenues, expenses, capital and our additional financing needs; implementing our business model and strategic plans for our products and technologies; competitive businesses and technologies and our industry; our ability to manage and grow our business by expanding our sales to existing customers or by introducing our products to new customers; our ability to develop and market new products; our ability to establish and maintain intellectual property protection for our products or to avoid or defend claims of infringement; the performance of third-party suppliers; our ability to hire and retain key personnel and to effectively manage our future growth; our ability to secure additional financing under future offerings; the volatility of the price of our common shares; our expectations regarding the use of the proceeds of our initial public offering (“IPO”); the potential effects of government regulation; the impact of COVID-19 on our business; and our expectations on market trends. For a more in-depth discussion of these and other factors that could affect our future results, performance or transactions, see the “Risk Factors” section included in our Form 10-Q filed with the Securities and Exchange Commission ( “SEC”) on November 12. 2021, and our other SEC filings. In view of these uncertainties, you should not place undue reliance on these forward-looking statements. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which one factor, or combination of factors, may cause a substantial difference between actual results and those contained in any futures contract. statements we can make. We qualify all forward-looking statements in this press release with these cautionary statements. Except as required by law, we do not undertake to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Investor contact
[email protected]

press contact
[email protected]

Related links
www.isoplexis.com

SOURCE IsoPlexis


Share.

Comments are closed.